July 2, 2014 / by / News
SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases now has issued patents in the EU, USA and most recenlty Australia. Details at https://www.google.com/patents/WO2007071052A1?cl=en&dq=2006329199&hl=en&… SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases is issued in throughout Europe. In the USA the US patent office awarded nearly 2 addtional
Read more
Australian S1226 patent granted
July 2, 2014 / by / News
SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases now has issued patents in the EU, USA and most recenlty Australia. Details at https://www.google.com/patents/WO2007071052A1?cl=en&dq=2006329199&hl=en&… SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases is issued in throughout Europe. In the USA the US patent office awarded nearly 2 addtional
Read more
SolAeroMed AGM 2014 minutes
June 12, 2014 / by / News
List of attendees: In person DC Birdsell Michael Flach Bryce Weaver Morenike Fadayomi Robert Commandeur Michael Smith Andrea Chiu John Butt Trish Smith Sharif Galal Pat Brown John Dennis Lorne Gould Megan McIntyre Evan Nelson Francis Green Gareth Lewis Cora Pieron Attending by phone Phyllis Kane Innovate Calgary Louis Bouchard Apologies: Richard Leigh (held
Read more
S1226 Phase I Successfuly COMPLETED Q2 2014
May 20, 2014 / by / News
We are pleased to share that the S1226 Phase I Successfuly COMPLETED. We are currently analyzing the data and writing up the study results for submission to Health Canada. We are very pleased with the results which encourage us to believe there are no serious safey issues associated with our S1226 asthma drug. Prof Francis
Read more